Related references
Note: Only part of the references are listed.Factor Xa Inhibitor-Related Intracranial Hemorrhage Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates
Nicholas G. Panos et al.
CIRCULATION (2020)
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
Megan E. Barra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
HEART RHYTHM (2019)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
Melanie N. Smith et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
Marwan Sheikh-Taha
INTERNAL AND EMERGENCY MEDICINE (2019)
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report
Gregory Y. H. Lip et al.
CHEST (2018)
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Jing Tao et al.
JOURNAL OF INTENSIVE CARE (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
Daniel M. Witt et al.
BLOOD ADVANCES (2018)
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH
N. Khorsand et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage
Jennifer A. Frontera et al.
NEUROCRITICAL CARE (2016)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah M. Siegal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding A Randomized, Plasma-Controlled, Phase IIIb Study
Ravi Sarode et al.
CIRCULATION (2013)
Share Paper
